CJC/IPA Protocol (CJC-1295 + Ipamorelin)
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
The CJC/IPA protocol refers to a pre-mixed blend of two growth hormone secretagogues — CJC-1295 (usually the no-DAC form, also called Mod GRF 1-29) and Ipamorelin — sold together in a single vial. Each peptide stimulates the release of the body’s own growth hormone through a different receptor, and they are combined because that pairing has been reported to work synergistically.
CJC-1295 is an analog of growth hormone-releasing hormone (GHRH). Ipamorelin is a selective growth hormone-releasing peptide (GHRP) that acts on the ghrelin receptor. Combining a GHRH analog with a GHRP is one of the most commonly discussed strategies in growth hormone secretagogue research.
Much of the direct human evidence covers the individual components rather than this specific premixed blend, and neither peptide is approved by a major regulator for therapeutic use. Products in this category are sold for research purposes only.
How it works
CJC-1295 mimics GHRH and signals the pituitary to release growth hormone, while Ipamorelin activates the ghrelin receptor (GHS-R1a) to promote growth hormone release through a separate, complementary pathway. Because the two mechanisms are independent, co-administration has been reported to produce a larger growth hormone response than either compound alone at matched doses.
Ipamorelin is noted in the literature for being relatively selective — in animal studies it stimulated growth hormone without markedly raising cortisol or prolactin, which is one reason it is often chosen for this kind of pairing. The precise combined effect in humans is not well characterized.
Reported benefits
- Increased pulsatile growth hormone release compared with either peptide alone (studied for)
- Support for recovery, lean body composition, and sleep quality (commonly reported, limited human data)
- A relatively selective growth hormone response with less impact on other hormones (animal data)
These are reported and studied effects, not guaranteed outcomes.
Considerations & side effects
Because rigorous human trials of this specific blend are lacking, its long-term safety profile is not well established. Commonly reported side effects for GH secretagogues include injection-site irritation, transient flushing, headache, water retention, and a tingling sensation. Sustained elevation of growth hormone and IGF-I can also affect insulin sensitivity, which is a consideration that warrants clinical oversight.
Purity and actual peptide content vary widely in the research-chemical market, and premixed blends add uncertainty about the ratio of the two components. This is not a substitute for evaluation and treatment by a qualified clinician.
Frequently asked
What is the CJC/IPA protocol?
It's a combination product that pairs CJC-1295 (typically the no-DAC form) with Ipamorelin in a single vial. The two peptides are studied together because they act on different receptors that both stimulate growth hormone release.
Why are CJC-1295 and Ipamorelin combined?
CJC-1295 is a GHRH analog and Ipamorelin is a ghrelin-receptor agonist. Research on GHRH-plus-GHRP pairings has reported a synergistic growth hormone response, which is the rationale for combining them.
Is this combination FDA-approved?
No. Neither CJC-1295 nor Ipamorelin is approved by the FDA or other major regulators for human therapeutic use, and blends are sold for research purposes only.
What is the difference between CJC-1295 with and without DAC?
DAC (Drug Affinity Complex) extends how long CJC-1295 circulates. Most blends use the no-DAC form, which is shorter-acting and often described as producing a more pulsatile pattern of growth hormone signaling.
How is the blend typically administered?
Most commonly by subcutaneous injection after reconstitution with bacteriostatic water, since both peptides come as a lyophilized powder.
References
- Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. ↗
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. ↗
- Bowers CY, et al. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. ↗
Related compounds
Triple GH secretagogue blend combining CJC-1295 (no DAC / Mod GRF 1-29) with two ghrelin mimetics, ipamorelin and GHRP-2, for amplified synergistic GH release. Sold as a single 9mg lyophilized vial.
Growth hormone releasing peptide (GHRP). Selective GH release without significant hunger or cortisol increase.
Premium growth hormone secretagogue blend combining Tesamorelin and Ipamorelin. Enhances GH release with visceral fat reduction benefits. Sold as a single pre-mixed vial.